MedPage Today8h
GLP-1 Agents and Suicide: Making Sense of 2024's Mixed Data
Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
KSJB AM2d
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Tyler Morning Telegraph2d
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Rome Sentinel2d
New York Among Minority of States Where Medicaid Doesn't Cover Obesity-Indicated GLP-1s
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer2d
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune2d
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Benefits Pro2d
Medicaid spending on GLP-1s exceeded $3.5B in past year
California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.
I've taken weight-loss jabs for 6 years, says SARAH VINE. Here's the TEN things everyone must know if they're considering it... and one VERY surprising benefit
There's no doubt that 2024 has been the year of semaglutide. In the space of just a few months, the drug, chiefly Ozempic and ...
WFMZ-TV2d
Pennsylvania Medicaid Spent $297.8M on GLP-1s for Obesity Over the Past 12 Months
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk ... for GLP-1 medications varies and the financial impact of these coverage differences. Data Source: ...